Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20244201 | 1.00 | OGA (0.41) | OGAHEXA | |
| SCHEMBL12349947 | 0.77 | OGA (0.44) | OGAHEXA | |
| SCHEMBL18970548 | 0.75 | OGA (0.47) | OGAHEXA | |
| SCHEMBL13339129 | 0.73 | OGA (0.58) | OGAHEXA | |
| SCHEMBL15521182 | 0.73 | OGA (0.58) | OGAHEXA | |
| SCHEMBL14426720 | 0.70 | OGA (0.44) | OGAHEXA | |
| SCHEMBL25768567 | 0.70 | OGA (0.48) | OGAHEXA | |
| SCHEMBL23938021 | 0.69 | OGA (0.37) | OGA | |
| SCHEMBL15521171 | 0.68 | OGA (0.45) | OGAHEXA | |
| SCHEMBL15521173 | 0.68 | OGA (0.45) | OGAHEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793583-B2 | Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy | AMICUS THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190135832-A1 | Novel Compounds And Methods For The Treatment Of Alzheimer?s Disease And/Or Cerebral Amyloid Angiopathy | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-05-09 | — | — | US | disclosed |
| US-10174054-B2 | Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy | AMICUS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9994589-B2 | Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy | AMICUS THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2017106288-A1 | NOVEL COMPOUNDS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND/OR CEREBRAL AMYLOID ANGIOPATHY | AMICUS THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166588-A1 | Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793583-B2 | Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy | APP, PSEN1, PSEN2 | OGA 570/4885HEXA 117/4885 |
| US-20170166588-A1 | Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy | APP, PSEN1, PSEN2 | OGA 570/4885HEXA 117/4885 |
| US-20190135832-A1 | Novel Compounds And Methods For The Treatment Of Alzheimer?s Disease And/Or Cerebral Amyloid Angiopathy | APP, PSEN2, PSEN1 | OGA 826/4885HEXA 140/4885 |
| US-10174054-B2 | Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy | APP, PSEN1, PSEN2 | OGA 570/4885HEXA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.